Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation

Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating.

My bull case for Allogene Therapeutics (ALLO) would again centre on cemacabtagene ansegedleucel successfully translating its strong early MRD clearance signal into a statistically significant EFS benefit. However, things are still quite far